ArticleBioactive materials2025
PKM2
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Circulating Metabolites Treat Human TMJ-OA by Eliminating Senescent Chondrocytes via the C1QBP/C1q/p14ARF Axis.Journal of extracellular vesicles · 2026Trial
- Bioengineered extracellular vesicles escape lysosomal degradation and deliver Tet-PKM2 for macrophage immunometabolic reprogramming and periodontitis treatment.Bioactive materials · 2026Article
- Biological mechanisms governing the periodontal regenerative microenvironment: cellular crosstalk, extracellular matrix remodelling, and immunomodulation.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic periodontitis (CP) is one of the most prevalent local inflammatory disorders and is associated with various systemic diseases. However, the relationship between local CP pathogenesis and systemic metabolic responses is not fully elucidated. In this study, we show that CP causes systemic inflammation, leading to apoptotic resistance and senescent cell accumulation, which are crucial for maintaining local inflammation in a CP mouse model. Eliminating senescent cells through systemic senolytic therapy ameliorate local CP pathological changes. Proteomic analysis reveals that CP patient plasma extracellular vesicles show upregulation of immune response-related proteins and downregulation of metabolic and apoptosis-related proteins, among which pyruvate kinase M2 (PKM2) was significantly reduced. Moreover, CP mice show reduced circulating apoptotic vesicles (apoVs), particularly those carrying PKM2. Systemic administration of PKM2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.